acut
respiratori
infect
ari
preval
worldwid
rival
diarrhea
lead
caus
death
develop
countri
impoverish
urban
popul
south
america
ari
symptom
may
present
almost
continu
basi
make
difficult
determin
symptomfre
day
estim
attack
rate
children
area
may
spend
time
respiratori
symptom
mostli
caus
upper
respiratori
infect
uri
strike
dispar
develop
develop
countri
regard
ari
epidemiolog
casefat
rate
lower
respiratori
infect
lri
mainli
pneumonia
bronchiol
influenza
children
year
age
may
reach
area
sever
communitybas
studi
establish
import
common
respiratori
viral
infect
tropic
countri
tabl
impoverish
popul
common
viral
infect
may
occur
simultan
measl
diarrhea
malnutrit
result
complex
interact
patholog
condit
carri
potenti
becom
lifethreaten
diseas
unlik
certain
pathogen
restrict
tropic
area
respiratori
virus
worldwid
distribut
effici
persontoperson
transmiss
impact
age
group
except
agent
eg
adenovirus
sever
acut
respiratori
syndrom
sar
coronaviru
rare
case
extrapulmonari
dissemin
respiratori
virus
replic
gener
restrict
respiratori
mucosa
human
healthcar
facilitybas
studi
acut
lri
alri
conduct
tropic
countri
tabl
respiratori
syncyti
viru
rsv
viru
frequent
detect
follow
parainfluenza
virus
adenovirus
influenza
virus
except
human
rhinoviru
hrv
human
coronavirus
hcov
report
frequent
studi
tropic
countri
probabl
difficulti
detect
although
previou
studi
shown
attend
daycar
center
risk
ari
provid
day
care
children
becom
import
econom
issu
develop
countri
mother
must
join
workforc
contribut
famili
incom
consist
studi
unit
state
elsewher
studi
found
high
burden
ari
young
lowincom
children
attend
day
care
salvador
brazil
specif
intervent
avail
reduc
impact
respiratori
virus
applic
intervent
may
hamper
epidemiolog
pattern
ari
socioeconom
differ
temper
develop
countri
compar
equatori
region
exampl
hous
condit
crowd
pose
challeng
optim
healthcar
strategi
tropic
incid
respiratori
virus
particularli
rsv
influenza
show
season
trend
tropic
area
associ
season
peak
respiratori
virus
gener
may
less
appar
fluctuat
temperatur
smaller
nutrit
educ
intervent
reinforc
breastfeed
vitamin
supplement
measl
facilit
access
oral
rehydr
therapi
may
signific
effect
morbid
mortal
due
lri
alon
associ
diarrhea
chapter
focu
attent
common
viral
respiratori
infect
whose
main
featur
summar
tabl
tri
highlight
featur
uniqu
develop
world
tropic
countri
influenza
activ
may
occur
yearround
well
outbreak
typic
temper
region
infect
caus
seriou
diseas
popul
weaken
malnutrit
limit
access
medic
care
note
predisposit
induc
influenza
superimpos
bacteri
infect
mainli
streptococcu
pneumonia
may
greatli
affect
morbid
mortal
mainli
among
impoverish
popul
addit
influenza
virus
reassort
sometim
cross
speci
barrier
gener
emerg
strain
may
caus
local
outbreak
potenti
pandem
enorm
impact
health
global
scale
influenza
virus
pleomorph
envelop
segment
negativestrand
rna
genom
belong
famili
orthomyxovirida
influenza
virus
distribut
three
generaa
b
cbase
antigen
nucleoprotein
np
matrix
protein
influenza
viru
classifi
subtyp
base
two
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
among
ha
na
subtyp
recogn
natur
ha
three
na
subtyp
identifi
human
isol
influenza
virus
howev
three
subtyp
ha
two
na
caus
pandem
sustain
circul
human
popul
recent
year
genom
influenza
virus
contain
eight
rna
segment
influenza
b
virus
seven
rna
segment
influenza
c
glycoprotein
ha
respons
attach
viru
sialic
acidcontain
cell
receptor
mediat
fusion
penetr
proteolyt
cleavag
ha
cellular
serin
proteas
expos
hydrophob
fusion
domain
mediat
membran
fusion
na
cleav
termin
sialic
acid
glycoconjug
present
respiratori
mucin
cell
progeni
virion
action
destroy
receptor
recogn
ha
allow
bud
viru
releas
infect
cell
spread
within
respiratori
tract
influenza
c
viru
contain
singl
surfac
glycoprotein
bind
receptor
promot
fusion
membran
also
cleav
sialic
acid
viru
bind
receptor
follow
intern
endosom
fusion
viral
endosom
membran
releas
genom
cytoplasm
transport
nucleu
influenza
virus
protein
serv
ion
channel
function
facilit
dissoci
rna
segment
virion
interior
transcript
negativestrand
genom
rna
positivestrand
messeng
rna
mrna
complementari
rna
crna
mediat
viral
rna
polymeras
complex
nucleu
crna
serv
templat
synthesi
negativestrand
virion
rna
genom
segment
mrna
direct
viral
protein
synthesi
newli
assembl
nucleocapsid
acquir
envelop
bud
cell
surfac
virus
full
complement
genom
segment
infecti
influenza
virus
primarili
virus
aquat
bird
particularli
duck
shore
bird
harbor
subtyp
recogn
date
select
subtyp
natur
infect
rang
terrestri
swine
hors
human
aquat
seal
mammal
influenza
b
viru
infect
human
uncommonli
seal
dog
cat
swine
influenza
c
viru
primarili
viru
human
depend
viru
type
subtyp
experiment
infect
induc
mice
ferret
chicken
swine
primat
virus
propag
primari
cultur
kidney
cell
continu
cell
line
mdck
vero
also
embryon
hen
egg
biolog
properti
influenza
virus
bind
erythrocyt
exploit
earli
detect
viru
cell
cultur
develop
serolog
assay
hemagglutin
inhibit
influenza
virus
inactiv
temperatur
lipid
solvent
acid
formaldehyd
ioniz
radiat
ultraviolet
uv
light
influenza
virus
occur
throughout
world
caus
highli
contagi
respiratori
infect
high
morbid
excess
mortal
season
peak
particularli
infant
elderli
develop
tropic
countri
influenza
associ
averag
ari
lead
physician
contact
appar
low
proport
probabl
repres
sever
case
sinc
children
year
age
tropic
africa
found
seroconvert
one
outbreak
previous
healthi
children
younger
year
age
hospit
influenza
rate
similar
adult
high
risk
influenza
influenza
account
great
number
outpati
visit
cours
antibiot
children
age
human
influenza
viru
introduc
malnourish
popul
limit
access
care
high
morbid
mortal
rate
occur
observ
madagascar
convent
influenza
subtyp
viru
associ
casefat
rate
approxim
contrari
remark
sharp
season
influenza
outbreak
temper
countri
season
pattern
tropic
countri
vari
studi
southern
india
thailand
influenza
occur
throughout
year
sporad
outbreak
wherea
consist
outbreak
junejuli
novemberjanuari
coincid
winter
season
southern
northern
hemispher
appar
associ
meteorolog
factor
philippin
influenza
frequent
novemb
januari
seneg
nigeria
taiwan
clear
associ
increas
rainfal
southeastern
brazil
argentina
well
south
africa
season
outbreak
influenza
occur
annual
may
august
mid
autumn
winter
associ
cooler
temperatur
rainfal
influenza
b
outbreak
occur
period
yet
less
frequent
influenza
temper
tropic
region
wherea
influenza
c
gener
nonseason
minor
chang
antigen
call
antigen
drift
caus
accumul
point
mutat
gene
code
influenza
ha
na
gener
new
strain
spread
annual
epidem
influenza
virus
b
c
less
prone
antigen
drift
major
antigen
chang
influenza
call
antigen
shift
result
emerg
novel
ha
subtyp
without
new
na
human
lack
signific
immun
may
caus
acquisit
new
gene
segment
genet
reassort
host
infect
simultan
human
anim
typic
avian
viru
reappear
subtyp
reservoir
swine
suscept
avian
human
influenza
virus
may
host
reassort
serv
mammalian
speci
avian
virus
adapt
novel
influenza
viru
subtyp
gener
shift
caus
catastroph
pandem
includ
three
last
centuri
spanish
flu
pandem
estim
caus
million
death
worldwid
asian
flu
hong
kong
flu
caus
estim
million
death
recent
cluster
human
infect
due
avian
influenza
particularli
subtyp
virus
asia
rais
concern
new
pandem
threat
highli
pathogen
avian
influenza
viru
result
reassort
among
sever
avian
virus
caus
lethal
outbreak
domest
poultri
sever
ill
death
among
human
case
hong
kong
outbreak
due
exposur
infect
poultri
live
poultri
market
later
contain
slaughter
viru
transmit
ineffici
person
person
februari
viru
caus
death
famili
visit
fujian
provinc
china
sinc
late
widescal
poultri
outbreak
due
viru
occur
least
asian
countri
interspeci
transmiss
human
occur
least
two
countri
caus
case
death
vietnam
thailand
virus
continu
reassort
evolv
antigen
extend
host
rang
document
infect
swine
felid
prolong
nonsymptomat
excret
duck
detect
migratori
bird
indic
viru
becom
endem
southeast
asia
avian
viru
human
receptor
specif
also
spread
throughout
asia
domest
poultri
pig
caus
mild
diseas
human
hong
kong
china
avian
viru
caus
conjunct
least
peopl
one
fatal
pneumonia
netherland
outbreak
contain
cull
quarantin
poultri
februari
highli
pathogen
viru
emerg
domest
poultri
british
columbia
two
document
human
case
conjunct
mild
flulik
ill
influenza
viru
transmit
person
person
larg
droplet
smallparticl
aerosol
well
possibl
fomit
hand
contamin
subsequ
selfinocul
rel
import
rout
uncertain
natur
influenza
ingest
infect
bird
led
infect
avian
virus
cat
secondari
attack
rate
may
reach
semiclos
popul
especi
among
schoolchildren
patient
debilit
underli
condit
live
rel
confin
nurs
home
resid
children
play
major
role
influenza
outbreak
respect
propag
epidem
viru
famili
commun
classic
influenza
start
abruptli
incub
period
day
fever
chill
malais
headach
myalgia
prostrat
often
accompani
nonproduct
cough
sore
throat
mild
rhinorrhea
system
complaint
last
day
wherea
sore
throat
hoars
cough
substern
discomfort
may
increas
sever
system
symptom
subsid
cough
asthenia
often
persist
week
longer
respiratori
symptom
may
minim
absent
initi
especi
elderli
infant
frail
elderli
person
lassitud
lethargi
confus
lowgrad
fever
sometim
gastrointestin
complaint
may
primari
find
influenza
b
tend
milder
influenza
influenza
c
typic
caus
cold
bronchiti
influenza
may
also
present
unexplain
fever
croup
laryngotracheobronch
vomit
diarrhea
neurolog
manifest
young
children
influenza
viru
infect
adult
subclin
influenza
caus
varieti
viral
respiratori
complic
includ
otiti
media
sinus
tracheobronch
pneumonia
young
children
bronchiol
croup
secondari
bacteri
infect
especi
pneumonia
caus
staphylococcu
aureu
streptococcu
pneumonia
haemophilu
influenza
common
complic
suspect
relaps
fever
chest
pain
cough
influenza
also
associ
invas
meningococc
infect
complic
includ
exacerb
asthma
chronic
bronchiti
congest
heart
failur
myositi
myoglobinur
renal
failur
meningoenceph
transvers
myeliti
polyneur
parot
myocard
arthriti
dissemin
intravascular
coagul
rare
occur
influenza
rey
syndrom
occur
fewer
per
case
influenza
patient
year
age
follow
use
salicyl
pregnant
women
human
immunodefici
viru
hiv
infect
patient
immunocompromis
host
higher
risk
sever
diseas
complic
viru
infect
respiratori
mucosa
caus
lytic
infect
cell
desquam
respiratori
epithelium
mononuclear
cell
infiltr
lamina
propria
alter
mucociliari
clearanc
tracheobronch
typic
featur
often
associ
prolong
abnorm
small
airway
pulmonari
function
airway
hyperreact
primari
influenza
viral
pneumonia
result
diffus
alveolar
damag
alveolar
hemorrhag
exud
hyalin
membran
later
reactiv
fibrosi
fatal
case
show
patholog
chang
nonrespiratori
organ
brain
congest
swell
myocardi
inflamm
fibrinoid
chang
arteriol
viral
replic
upper
respiratori
tract
gener
peak
within
day
symptom
onset
depend
age
prior
immunolog
experi
continu
day
sever
ill
broadli
correl
upper
respiratori
tract
viral
level
constitut
symptom
influenza
due
part
releas
proinflammatori
cytokin
chemokin
level
interferon
tumor
necrosi
factor
interleukin
chemokin
increas
nasal
secret
ifn
increas
blood
human
influenza
tissu
tropism
strain
influenza
viru
depend
among
factor
combin
suscept
ha
cleav
tissu
avail
proteas
specif
cleav
thu
render
viru
infecti
extrapulmonari
dissemin
viru
uncommonli
document
human
system
spread
regular
featur
highli
pathogen
avian
virus
chicken
sometim
rodent
mammalian
host
serum
secretori
antibodi
direct
ha
na
appear
day
infect
protect
reinfect
homolog
strain
durabl
follow
natur
infect
correl
serum
nasal
neutral
antibodi
level
princip
direct
ha
vaccineinduc
protect
may
last
year
homotyp
viru
infect
also
induc
cellmedi
immun
detect
day
infect
seem
import
recoveri
cytotox
tlymphocyt
respons
intern
protein
may
provid
degre
heterosubtyp
immun
diagnosi
influenza
frequent
made
basi
clinic
epidemiolog
inform
higher
index
suspicion
laboratori
diagnost
need
outsid
season
particularli
sporad
individu
case
unexplain
outbreak
febril
respiratori
ill
viral
isol
respiratori
specimen
done
sever
type
cell
eg
prmk
mdck
remain
current
standard
presenc
viru
may
detect
cell
cultur
hemadsorpt
guinea
pig
erythrocyt
cytopath
effect
cpe
visibl
blind
hemadsorpt
posit
day
inocul
almost
posit
sampl
confirm
isol
done
hemagglutin
inhibit
immunofluoresc
typespecif
antisera
diagnosi
also
made
day
immunofluoresc
monolay
mdck
cell
inocul
centrifug
shellvial
conserv
influenza
antigen
np
directli
clinic
sampl
detect
one
sever
techniqu
eg
immunofluoresc
enzym
immunoassay
eia
multipl
pointofcar
kit
commerci
avail
turnaround
time
minut
one
commerci
assay
base
detect
influenzaspecif
na
activ
sensit
assay
higher
children
adult
gener
depend
durat
ill
sampl
type
sever
format
revers
transcriptionpolymeras
chain
reaction
rtpcr
assay
use
detect
influenza
b
rna
clinic
sampl
advantag
detect
genom
noninfecti
viru
time
perform
rtpcr
longer
cost
may
lower
commerci
rapid
antigen
detect
kit
especi
develop
countri
realtim
rtpcr
enabl
develop
assay
provid
rapid
quantit
detect
influenza
b
high
sensit
assay
great
potenti
replac
method
simultan
rapid
highli
sensit
quantit
amen
use
multiplex
format
might
includ
probe
sever
differ
respiratori
pathogen
howev
cost
still
prohibit
laboratori
develop
nation
serolog
diagnosi
influenza
use
pair
acut
convalesc
serum
done
retrospect
varieti
techniqu
mainli
serolog
survey
purpos
amantadin
rimantadin
ion
channel
blocker
inhibit
influenza
viru
replic
uncoat
step
uncompl
influenza
adult
without
underli
diseas
treatment
either
drug
reduc
durat
influenza
ill
approxim
day
start
earli
within
hour
onset
symptom
amantadin
excret
unchang
state
urin
rimantadin
extens
metabol
absorpt
less
dose
excret
unchang
urin
elderli
person
need
half
dose
achiev
similar
plasma
level
amantadin
rimantadin
may
caus
gastrointestin
upset
central
nervou
system
side
effect
central
nervou
system
cn
intoler
common
amantadin
sever
manifest
agit
psychosi
seizur
coma
mild
complaint
includ
insomnia
dizzi
anxieti
dri
mouth
anorexia
nausea
revers
upon
discontinu
amantadin
rimantadin
market
tablet
syrup
recommend
dose
mg
twice
daili
adult
older
year
age
mgday
patient
year
age
children
age
year
rimantadin
dose
mgkgday
maximum
mgday
suggest
dose
reduct
proport
creatinin
clearanc
clcr
suggest
patient
renal
insuffici
amantadin
clcr
rimantadin
clcr
influenza
viru
resist
amantadinerimantadin
emerg
approxim
one
third
treat
patient
virus
transmiss
close
contact
caus
typic
influenza
ill
resist
drug
render
ineffect
sometim
present
natur
includ
recent
human
isol
viru
neuraminidas
inhibitor
zanamivir
oseltamivir
inhibit
influenza
b
virus
block
activ
site
enzym
cleavag
sialic
acid
thu
inhibit
viru
releas
infect
cell
spread
within
respiratori
tract
adult
children
older
year
inhal
zanamivir
mg
twice
daili
day
provid
reduct
ill
reduc
antibiot
use
lower
respiratori
complic
zanamivir
gener
well
toler
may
uncommonli
induc
bronchospasm
particularli
influenza
preexist
airway
diseas
oseltamivir
mg
oral
twice
daili
day
reduc
ill
sever
time
resumpt
daili
activ
day
rate
complic
lead
antibiot
prescript
hospit
adult
children
year
age
oseltamivir
reduc
frequenc
otiti
media
consequ
antibiot
prescript
side
effect
includ
mildtomoder
nausea
emesi
dosag
neuraminidas
inhibitor
need
adjust
elderli
resist
emerg
uncommon
drug
although
recent
studi
children
treat
oseltamivir
detect
drugresist
virus
often
associ
prolong
viral
excret
show
children
sourc
viral
transmiss
even
day
treatment
antipyreticanalges
drug
may
use
influenzainduc
fever
ach
aspirin
avoid
associ
rey
syndrom
immun
formalininactiv
liveattenu
multival
influenza
viru
vaccin
chemoprophylaxi
influenza
viru
method
avail
prevent
influenza
influenza
vaccin
use
prior
influenza
season
current
includ
one
strain
influenza
b
two
strain
subtyp
influenza
viru
chosen
world
health
organ
surveil
network
among
virus
like
circul
next
influenza
season
inactiv
vaccin
approxim
efficaci
prevent
ill
healthi
children
adult
also
reduc
influenzarel
hospit
mortal
elderli
highrisk
patient
center
diseas
control
prevent
cdc
recommend
immun
person
age
year
older
resid
nurs
home
children
adult
chronic
cardiovascular
pulmonari
diseas
includ
asthma
person
chronic
ill
diabet
mellitu
renal
dysfunct
hemoglobinopathi
immunosuppress
patient
includ
hiv
infect
children
adolesc
chronic
aspirin
therapi
may
develop
postinfluenza
rey
syndrom
women
pregnant
influenza
season
children
age
month
transmit
influenza
person
high
risk
healthcar
worker
household
contact
high
risk
includ
children
month
age
crew
member
cruis
ship
provid
essenti
servic
unimmun
travel
area
influenza
may
circul
includ
tropic
southern
hemispher
april
septemb
travel
larg
organ
tourist
group
addit
vaccin
made
avail
anyon
interest
reduc
likelihood
becom
ill
influenza
inactiv
vaccin
administ
singl
intramuscular
im
dose
shortli
influenza
season
two
dose
previous
unimmun
children
year
age
safe
pregnanc
avoid
person
histori
anaphylact
reaction
egg
vaccin
safeti
efficaci
children
extens
evalu
shown
favor
safeti
profil
efficaci
children
inactiv
vaccin
current
recommend
children
younger
month
vaccin
household
contact
caregiv
reduc
risk
highrisk
children
contract
influenza
healthi
peopl
age
year
contact
immunosuppress
patient
receiv
either
inactiv
intranas
liveattenu
vaccin
influenza
inactiv
vaccin
recent
introduc
mani
tropic
area
world
composit
base
influenza
virus
circul
southern
hemispher
vaccin
given
prior
influenza
season
countri
southern
hemispher
may
juli
south
america
annual
vaccin
elderli
reduc
hospit
mortal
respiratori
diseas
continu
surveil
alreadi
shown
region
variat
circul
influenza
viru
strain
taken
consider
formul
influenza
vaccin
composit
appropri
south
america
liveattenu
coldadapt
vaccin
administ
intranas
well
toler
genet
stabl
rare
transmiss
advantag
induc
local
secretori
immunoglobulin
iga
respons
potenti
interfer
compon
two
dose
may
requir
young
children
vaccin
licens
unit
state
becom
option
healthi
person
age
year
includ
close
contact
group
high
risk
want
avoid
influenza
vaccin
recommend
person
asthma
chronic
disord
pulmonari
cardiovascular
system
person
underli
medic
condit
includ
diabet
renal
dysfunct
hemoglobinopathi
person
known
suspect
immunodefici
diseas
receiv
immunosuppress
therapi
children
adolesc
receiv
aspirin
salicyl
person
histori
syndrom
pregnant
women
person
histori
hypersensit
egg
coldadapt
trival
influenza
vaccin
highli
effect
phase
studi
prevent
cultureconfirm
influenza
healthi
children
provid
protect
drift
variant
strain
studi
young
middleag
adult
efficaci
gener
compar
inactiv
vaccin
investig
approach
explor
influenza
vaccin
develop
includ
recombin
ha
produc
insect
cell
virosom
incorpor
surfac
glycoprotein
protein
conjug
hepat
b
viru
core
nake
dna
encod
influenza
viru
nucleoprotein
ha
cell
culturebas
vaccin
mdck
vero
approv
europ
may
offer
altern
limit
current
egggrown
vaccin
techniqu
revers
genet
use
rapidli
produc
candid
vaccin
potenti
pandem
threat
virus
amantadin
rimantadin
approv
use
effect
prophylaxi
influenza
outbreak
unvaccin
elderli
person
immunodefici
patient
patient
chronic
care
institut
experienc
outbreak
person
could
vaccin
receiv
vaccin
strain
differ
outbreak
strain
may
receiv
prophylaxi
amantadin
rimantadin
prophylaxi
start
earli
possibl
dose
equival
use
therapi
continu
week
end
outbreak
total
least
week
amantadineand
rimantadineresist
mutant
influenza
viru
occur
treat
patient
may
associ
failur
drug
prophylaxi
oseltamivir
mg
twice
daili
inhal
zanamivir
mgdose
twice
daili
effect
prophylaxi
influenza
outbreak
oseltamivir
approv
indic
unit
state
antivir
agent
especi
neuraminidas
inhibitor
could
significantli
help
control
futur
influenza
pandem
reduc
lower
respiratori
complic
hospit
well
potenti
persontoperson
transmiss
howev
suppli
limit
pose
real
difficulti
therefor
polici
ensur
reason
suppli
drug
well
direct
optim
use
limit
suppli
import
issu
consid
respiratori
syncyti
viru
rsv
singl
import
viral
caus
lower
respiratori
diseas
major
caus
morbid
mortal
children
worldwid
rsv
lead
caus
hospit
young
children
develop
develop
countri
tropic
area
rsv
frequent
isol
viru
hospitalbas
ari
studi
children
agent
rsv
known
human
pathogen
genu
pneumoviru
famili
paramyxovirida
pleomorph
rna
viru
helic
nucleocapsid
lipidcontain
envelop
antigen
differ
surfac
glycoprotein
g
permit
classif
rsv
group
b
antigen
subgroup
interact
rsv
envelop
glycoprotein
g
glycosaminoglycan
enabl
adher
cell
surfac
howev
g
proteinindepend
mechan
attach
must
exist
sinc
mutant
devoid
g
protein
also
enter
host
cell
rsv
enter
cell
fusion
viral
envelop
cell
membran
process
mediat
bind
viral
f
protein
cell
gtpase
rhoa
syncytia
result
fusion
infect
cell
adjac
one
major
featur
cytopath
effect
paramyxovirus
cytoplasm
negativestrand
rna
transcrib
viral
transcriptas
mrna
direct
viral
protein
synthesi
intermedi
positivestrand
fulllength
crna
serv
templat
synthesi
progeni
negativestrand
rna
bud
cell
membran
virion
acquir
glycoproteincontain
envelop
rsv
caus
asymptomat
infect
varieti
experiment
anim
natur
infect
occur
human
chimpanze
rsv
grow
well
sever
human
heteroploid
cell
line
hela
sensit
ether
chloroform
deterg
ph
less
rsv
inactiv
surviv
poorli
porou
surfac
lose
infect
significantli
slow
freez
storag
temperatur
rsv
occur
worldwid
caus
annual
outbreak
temper
climat
winter
earli
spring
sporad
case
throughout
year
tropic
region
temperatur
fluctuat
smaller
signific
season
variabl
often
rainfal
rsv
outbreak
tend
occur
raini
season
case
malaysia
hong
kong
india
papua
new
guinea
colombia
kenya
gambia
interestingli
singapor
rsv
peak
activ
occur
march
august
period
higher
temperatur
higher
daytoday
temperatur
variat
lower
rel
humid
southeast
brazil
rsv
occur
season
within
broader
rang
month
februari
juli
raini
season
temperatur
tend
cooler
slight
variat
year
year
region
averag
winter
temperatur
colder
paulo
citi
southernmost
part
brazil
well
argentina
rsv
peak
activ
tend
occur
juli
august
children
specif
serum
rsv
antibodi
age
year
reinfect
occur
throughout
life
one
subtyp
either
rsv
group
may
cocircul
one
season
group
predomin
chang
year
year
without
appar
correl
clinic
epidemiolog
characterist
ill
caus
rsv
transmiss
requir
close
contact
occur
either
largeparticl
aerosol
contamin
hand
inocul
eye
nose
secondari
infect
famili
contact
index
case
common
averag
incub
period
rang
day
estim
infant
rsv
infect
requir
medic
attent
hospit
estim
children
bronchiol
first
year
life
infect
caus
rsv
southeast
brazil
rsv
lead
caus
lower
respiratori
tract
infect
children
younger
year
age
respons
hospit
age
group
peak
month
spectrum
ill
caus
rsv
rang
mild
uri
sever
lri
includ
pneumonia
bronchiol
tracheobronch
croup
infant
young
children
uri
fever
otiti
media
common
outbreak
rsv
rna
detect
middl
ear
effus
children
rsv
infect
acut
otiti
media
frequent
lri
caus
rsv
infant
bronchiol
usual
preced
day
uri
symptom
progress
lower
respiratori
tract
involv
character
tachypnea
dyspnea
cough
expiratori
wheez
air
trap
sever
case
intercost
muscl
retract
cyanosi
fever
present
infant
chest
radiograph
may
show
hyperaer
lung
sometim
segment
atelectasi
blood
count
usual
show
lymphocytosi
increas
neutrophil
left
shift
could
associ
bacteri
superinfect
frequent
bacteri
superinfect
children
rsv
infect
acut
otiti
media
may
found
children
brochiol
howev
seriou
bacteri
infect
may
requir
sepsi
workup
uncommon
previous
healthi
infant
rsv
infect
may
differ
howev
develop
tropic
area
rsv
frequent
caus
infect
children
previous
debilit
diseas
malnutrit
infant
congenit
heart
diseas
prematur
infant
infant
underli
pulmonari
condit
cystic
fibrosi
bronchopulmonari
dysplasia
well
immunocompromis
host
age
risk
sever
fatal
rsv
infect
hivinfect
children
rsv
infect
higher
rate
pneumonia
prolong
ill
viru
shed
gener
sever
rsv
diseas
increas
differenti
diagnosi
acut
bronchiol
includ
asthma
pneumonia
congenit
heart
lung
diseas
cystic
fibrosi
particular
clinic
sign
gener
accur
predictor
specif
viral
caus
studi
conduct
philippin
wheez
signific
predictor
viral
lri
manifest
higher
sever
chest
indraw
cyanosi
often
associ
bacteri
lri
frequent
rsv
ill
children
year
age
adult
uri
coryza
cough
sore
throat
hoars
often
accompani
lowgrad
fever
exacerb
chronic
pulmonari
diseas
wheez
also
seen
adult
rsv
infect
role
rsv
infect
caus
wheez
asthma
exacerb
infant
well
establish
studi
conduct
temper
area
similar
observ
made
emerg
room
studi
conduct
southeast
brazil
found
infect
respiratori
virus
especi
rsv
famili
histori
allergi
independ
associ
wheez
similar
find
observ
urban
nigerian
preschool
children
rsv
increasingli
recogn
caus
lri
elderli
mainli
character
interstiti
pneumonia
prolong
cough
dyspnea
person
chronic
pulmonari
condit
consid
differenti
diagnosi
flulik
ill
rsv
replic
respiratori
epithelium
reach
titer
high
tcid
ml
nasal
secret
infect
babi
viru
shed
may
prolong
week
symptom
disappear
rsv
spread
cell
cell
may
involv
entir
respiratori
tree
reach
bronchiol
day
onset
rhinorrhea
replic
bronchiolar
epithelium
caus
necrosi
ciliat
cell
syncytia
format
peribronchiolar
inflamm
abund
lymphocyt
macrophag
impair
secret
clearanc
result
small
airway
obstruct
hyperinfl
characterist
bronchiol
pneumonia
frequent
coexist
evidenc
interstiti
mononuclear
infiltr
eosinophil
cytoplasm
inclus
epitheli
cell
multinucl
giant
cell
sever
rsv
diseas
occur
young
babi
whose
immatur
airway
may
unabl
compens
patholog
chang
natur
acquir
immun
rsv
incomplet
shortliv
sever
ill
tend
decreas
reinfect
local
secretori
iga
correl
better
protect
serum
antibodi
level
age
preexist
virusspecif
matern
antibodi
influenc
develop
neutral
antibodi
cellmedi
immun
respons
central
recoveri
rsv
infect
patient
suppress
cellmedi
immun
respons
risk
sever
rsv
pulmonari
diseas
fatal
outcom
type
immun
respons
viru
probabl
major
factor
develop
wheez
asthma
exacerb
bia
toward
cytokin
respons
seem
associ
sever
diseas
wherea
respons
lead
effect
viral
clearanc
milder
ill
viru
gener
trigger
respons
preexist
defici
may
associ
diseas
sever
children
suggest
rsv
bronchiol
may
marker
predisposit
wheez
asthma
later
life
children
vaccin
formalininactiv
rsv
vaccin
develop
sever
diseas
expos
natur
infect
appar
consequ
imbal
protect
immunopatholog
tcell
respons
elicit
previou
parenter
immun
inactiv
rsv
would
favor
cytokin
pattern
respons
subsequ
rsv
infect
wherea
previou
natur
infect
would
favor
pattern
respons
reinfect
nasopharyng
aspir
swab
nasal
wash
lower
respiratori
sampl
appropri
specimen
rsv
isol
usual
accomplish
cultur
cell
line
rsv
induc
syncytia
day
rsv
antigen
detect
eia
includ
membranebas
eia
sensit
specif
requir
virtual
equip
make
ideal
field
studi
rapid
rsv
detect
exfoli
respiratori
cell
may
even
sensit
eiabas
method
increas
use
rapid
test
facilit
assess
rsv
tropic
area
ideal
combin
rapid
method
viral
isol
use
maxim
rsv
detect
cost
may
still
prohibit
meager
resourc
avail
tropic
area
detect
rsv
rna
convent
rtpcr
shown
suboptim
sensit
especi
compar
easytoperform
sensit
rapid
method
howev
recent
develop
assay
base
realtim
rtpcr
prove
sensit
convent
rtpcr
assay
ad
conveni
rapid
quantit
amen
simultan
detect
subtyp
rsv
directli
clinic
specimen
rsv
serolog
limit
valu
case
manag
may
use
epidemiolog
survey
treatment
uri
caus
rsv
requir
specif
treatment
antibiot
need
bacteri
otiti
media
sinus
present
support
treatment
infant
rsv
bronchiol
consist
basic
prevent
hypoxemia
electrolyt
imbal
addit
aerosol
bronchodil
lack
obviou
correl
radiolog
find
diseas
sever
suggest
chest
film
recommend
sever
ill
deterior
infant
prevent
hypoxemia
requir
may
vari
simpl
remov
respiratori
secret
proper
posit
infant
mechan
respiratori
assist
even
extracorpor
membran
oxygen
ecmo
puls
oximetri
advoc
assess
oxygen
need
tropic
develop
area
oximet
may
avail
serial
clinic
assess
essenti
monitor
diseas
progress
purpos
crackl
cyanosi
seem
correl
better
hypoxemia
tachypnea
intercost
retract
correct
hypoxemia
accomplish
lower
oxygen
concentr
oxygen
humidifi
salin
deliv
mask
head
box
tent
unavail
role
corticosteroid
remain
unclear
evid
benefici
antivir
drug
current
approv
treatment
infant
rsv
synthet
nucleosid
ribavirin
deliv
smallparticl
aerosol
via
mist
tent
mask
oxygen
hood
ventil
recommend
infant
young
children
underli
condit
congenit
heart
diseas
cystic
fibrosi
immunosuppress
prematur
infant
infant
younger
week
age
sever
ill
infant
may
also
consid
therapi
aerosol
ribavirin
well
toler
expens
prolong
administr
requir
facil
may
avail
impoverish
tropic
area
passiv
immunotherapi
rsv
immunoglobulin
combin
aerosol
ribavirin
improv
outcom
rsv
pneumonia
bone
marrow
transplant
patient
use
rsvintraven
immunoglobulin
ivig
human
monoclon
antibodi
rsv
shown
benefit
treatment
rsv
infect
infant
vaccin
current
avail
rsv
prophylaxi
diseas
enhanc
caus
formalininactiv
vaccin
plu
result
recent
unsuccess
trial
liveattenu
vaccin
significantli
slow
progress
toward
rsv
vaccin
purifi
fusion
protein
vaccin
test
safeti
immunogen
seroposit
children
older
month
associ
reduct
lower
respiratori
tract
ill
rsv
infect
rate
children
cystic
fibrosi
candid
subunit
vaccin
well
intranas
liveattenu
vaccin
test
highrisk
children
underli
bronchopulmonari
diseas
passiv
immun
highrisk
infant
monthli
infus
rsv
immunoglobulin
rsv
season
reduc
incid
sever
rsv
infect
highrisk
children
costli
intervent
avail
mean
protect
highrisk
children
seriou
rsv
lri
monthli
intramuscular
inject
human
monoclon
antibodi
consid
passiv
immunoprophylaxi
rsv
season
highrisk
infant
preterm
infant
less
month
old
children
congenit
heart
diseas
children
less
year
age
bronchopulmonari
dysplasia
hospit
infant
rsv
infect
isol
group
prevent
crossinfect
hand
wash
use
eyenos
goggl
gown
glove
decontamin
surfac
fomit
addit
nosocomi
infect
control
measur
human
parainfluenza
virus
hpiv
singl
frequent
caus
croup
infant
children
worldwid
second
rsv
caus
lri
infant
littl
known
epidemiolog
hpiv
tropic
countri
virus
detect
children
hospitalbas
ari
studi
develop
countri
hpiv
distribut
two
genera
famili
paramyxovirida
share
structur
biolog
characterist
alreadi
mention
rsv
section
hpiv
classifi
antigen
type
subtyp
b
hpiv
type
classifi
genu
respiroviru
hpiv
type
genu
rubulaviru
type
frequent
associ
lri
children
immunocompromis
chronic
ill
elderli
wherea
caus
mostli
uri
children
adult
bind
hpiv
sialic
acid
cell
membran
mediat
glycoprotein
hn
contain
hemagglutinin
neuraminidas
activ
fusion
viral
cell
membran
mediat
viral
f
protein
cleav
cellular
proteolyt
enzym
insid
cell
cycl
similar
paramyxovirida
summar
rsv
section
hpiv
propag
primari
simian
human
kidney
cell
sever
cell
line
vero
mdck
bhk
hela
varieti
experiment
anim
undergo
asymptomat
infect
piv
higher
primat
develop
symptom
epidemiolog
primari
hpiv
infect
occur
earli
childhood
age
virtual
children
seroposit
estim
one
third
viral
lri
children
unit
state
caus
temper
region
caus
epidem
fall
altern
year
either
cocircul
altern
one
anoth
biennial
pattern
found
hemispher
caus
croup
epidem
wherea
frequent
caus
ill
milder
manifest
although
also
caus
croup
occur
endem
throughout
year
sporad
spring
outbreak
mainli
among
infant
occur
sporad
throughout
year
children
adult
tropic
area
hpiv
may
account
child
hospit
admiss
due
lri
communitybas
ari
studi
children
age
year
show
higher
hpiv
activ
raini
season
tropic
countri
hpiv
frequent
virus
detect
schoolag
children
bronchial
asthma
exacerb
urban
nigeria
hpiv
spread
mainli
within
famili
close
commun
nurseri
daycar
center
pediatr
ward
high
secondari
attack
rate
longitudin
studi
conduct
children
less
year
age
ari
daycar
center
lowincom
famili
northeast
brazil
hpiv
repres
virus
detect
viru
persist
long
environ
transmit
mainli
larg
droplet
fomit
viral
shed
usual
last
day
shed
hpiv
month
report
young
children
immunosuppress
host
primari
hpiv
infect
may
caus
rhiniti
pharyng
laryngotracheobronch
croup
bronchiol
pneumonia
approxim
two
third
piv
infect
children
result
febril
uri
associ
otiti
media
remain
one
third
piv
infect
case
croup
bronchiol
pneumonia
hpiv
mainli
type
caus
case
croup
croup
strike
clinic
present
hpiv
infect
common
age
month
croup
manifest
inspiratori
stridor
bark
cough
hoars
caus
subglott
edema
preced
rhinorrhea
mild
cough
lowgrad
fever
children
recov
day
may
develop
bronchiol
pneumonia
present
bronchopneumoniacroup
syndrom
sinc
immun
hpiv
incomplet
infect
tend
occur
throughout
life
littl
known
hpiv
infect
adult
gener
adult
nonspecif
uri
commonli
hoars
hpiv
caus
particularli
sever
diseas
immunocompromis
host
especi
children
sever
combin
immunodefici
bone
marrow
transplant
patient
mortal
bone
marrow
transplant
patient
hpiv
infect
vari
seri
hpiv
replic
ciliat
epitheli
cell
caus
cytolysi
respiratori
mucosa
infect
begin
upper
respiratori
tract
tend
dissemin
respiratori
tree
larynx
trachea
mostli
involv
croup
syndrom
extens
involv
lower
respiratori
tree
may
present
tracheobronch
bronchopneumonia
bronchiol
similar
influenza
factor
determin
extent
hpiv
infect
includ
suscept
viral
f
protein
cleav
tissuespecif
differ
product
proteas
cleav
host
immun
larg
mediat
humor
immun
two
surfac
protein
hn
f
virtual
children
age
year
seroconvert
hpiv
gener
first
later
also
school
age
signific
proport
children
seroconvert
also
secretori
antibodi
target
hn
glycoprotein
best
marker
protect
piv
protect
confer
antibodi
limit
repeat
infect
develop
tcell
immun
respons
seem
involv
clearanc
viru
addit
develop
inflammatori
infiltr
edema
excess
mucu
secret
immunocompromis
host
may
develop
progress
even
lethal
diseas
like
rsv
piv
caus
mononuclear
interstiti
infiltr
epitheli
necrosi
inflammatori
exud
alveoli
hyalin
membran
format
lung
piv
present
respiratori
secret
day
onset
symptom
isol
monkey
kidney
primari
cell
sever
continu
cell
line
viru
detect
monolay
hemadsorpt
guinea
pig
erythrocyt
around
day
inocul
confirm
shellvial
assay
develop
hpiv
detect
mix
result
exfoli
respiratori
epitheli
cell
produc
conflict
sometim
disappoint
result
studi
report
sensit
best
detect
viral
rna
rtpcr
includ
commerci
avail
multiplex
assay
sever
respiratori
virus
enhanc
sensit
detect
hpiv
clinic
sampl
realtim
pcr
respiratori
virus
multiplex
format
sensit
specif
hpiv
present
support
symptomat
treatment
avail
piv
infect
manag
croup
includ
supplement
oxygen
racem
epinephrin
nebul
hospit
patient
mist
therapi
although
tradit
proven
valu
shortterm
highdos
system
corticosteroid
may
reduc
need
intub
nebul
budesonid
rapid
effect
safe
efficaci
nebul
epinephrin
moder
sever
croup
sever
antivir
agent
vitro
activ
hpiv
none
reach
clinic
test
anecdot
report
reduc
hpiv
shed
immunocompromis
patient
treat
ribavirin
find
resist
scrutini
futur
possibl
includ
bcx
bcx
compound
whose
design
base
threedimension
structur
hn
protein
inhibit
hemagglutinin
neuraminidas
activ
protein
effect
vitro
anim
model
intervent
avail
prevent
hpiv
infect
earli
trial
inactiv
hpiv
vaccin
unsuccess
recent
liveattenu
coldadapt
vaccin
found
immunogen
children
young
month
age
hold
promis
develop
vaccin
test
combin
liveattenu
rsv
vaccin
candid
show
approach
feasibl
deserv
studi
character
hpiv
protein
hn
f
led
develop
subunit
immunogen
show
efficaci
anim
model
human
rhinovirus
hrv
frequent
respiratori
pathogen
human
frequent
isol
virus
children
year
age
ari
urban
slum
northeast
brazil
human
rhinovirus
small
nonenvelop
positivestrand
rna
virus
famili
picornavirida
identifi
serotyp
hrv
serotyp
classifi
accord
receptorspecif
three
group
major
group
includ
serotyp
whose
receptor
intercellular
adhes
minor
group
contain
serotyp
whose
receptor
lowdens
lipoprotein
receptor
ldlr
remain
serotyp
util
sialoprotein
cell
receptor
unlik
picornavirus
hrv
acidlabil
properti
distinguish
enterovirus
hrv
genom
monocistron
singlestrand
rna
pack
icosahedr
capsid
compos
pentam
surround
fivefold
vertex
pentam
contain
canyon
contain
receptor
bind
site
follow
receptor
bind
viral
positivestrand
rna
releas
cytoplasm
direct
synthesi
polyprotein
whose
cleavag
product
includ
rna
polymeras
enzym
produc
expand
pool
positivestrand
rna
use
templat
intermedi
negativestrand
rna
positivestrand
rna
either
translat
virion
protein
packag
genom
newli
assembl
virion
hrv
replic
cycl
take
place
cytoplasm
matur
virion
releas
host
cell
lyse
hrv
resist
ethanol
ether
chloroform
nonion
deterg
sensit
uv
light
ph
lower
higher
halogen
chlorin
bromin
iodin
phenol
disinfect
stabl
day
environment
surfac
year
minu
hrv
infect
higher
primat
caus
ill
human
sever
cell
line
primat
origin
support
hrv
propag
certain
strain
hela
cell
human
embryon
fibroblast
provid
higher
sensit
hrv
isol
clinic
specimen
optim
growth
temperatur
hrv
hrv
infect
occur
peopl
contin
includ
remot
locat
popul
group
bushmen
kalahari
desert
nativ
alaskan
isol
amazon
indian
tribe
hrv
estim
caus
autumn
cold
temper
climat
tropic
countri
communitybas
studi
viral
ari
use
adequ
hrv
detect
method
limit
assess
actual
impact
hrv
area
howev
avail
evid
indic
hrv
frequent
associ
ari
children
brazil
fortaleza
citi
northeast
brazil
hrv
detect
isol
cell
cultur
repres
virus
children
year
age
ari
salvador
anoth
citi
region
hrv
repres
virus
detect
rtpcr
associ
ari
children
younger
year
age
attend
daycar
center
underprivileg
data
frequenc
hrv
among
adult
tropic
countri
even
scarc
singapor
hrv
detect
sampl
obtain
adult
ari
symptom
attend
primari
care
center
hrv
transmiss
requir
close
exposur
occur
mainli
handtohand
contact
follow
selfinocul
eye
nose
also
airborn
spread
hrv
reach
nasal
caviti
infect
occur
virtual
suscept
subject
approxim
infect
develop
ill
incub
children
play
central
role
spread
viru
household
evid
suggest
indoor
hrv
transmiss
favor
high
rel
humid
crowd
young
children
occur
unit
state
begin
school
term
may
explain
autumn
season
peak
hrv
tropic
northeastern
brazil
howev
rel
humid
remain
reach
raini
season
longitudin
studi
found
obviou
hrv
season
hrv
cold
indistinguish
cold
viral
caus
consist
nasal
discharg
nasal
obstruct
sneez
sore
scratchi
throat
hoars
cough
headach
facial
ear
pressur
may
present
fever
malais
uncommon
symptom
last
approxim
day
may
persist
week
case
infant
toddler
may
display
nasal
discharg
otherwis
asymptomat
major
patient
obstruct
mucos
abnorm
sinu
caviti
eustachian
tube
middl
ear
predispos
secondari
bacteri
sinus
otiti
media
complic
found
approxim
cold
hrv
rna
may
detect
rtpcr
maxillari
sinu
brush
adult
present
acut
sinus
sampl
middl
ear
fluid
children
less
year
age
diagnosi
acut
otiti
media
hrv
frequent
associ
exacerb
chronic
obstruct
pulmonari
diseas
asthma
attack
children
year
age
adult
hrv
replic
restrict
respiratori
epithelium
take
place
scatter
ciliat
cell
nose
noncili
cell
nasopharynx
tropism
seem
consequ
receptor
avail
infect
limit
number
cell
trigger
releas
cytokin
chemokin
inflammatori
mediat
togeth
stimul
local
parasympathet
nerv
end
result
cold
symptom
kinin
prostaglandin
proinflammatori
cytokin
chemokin
may
contribut
vasodil
increas
vascular
permeabl
influx
polymorphonuclear
leukocyt
exocrin
gland
secret
nerv
end
stimul
result
nasal
obstruct
rhinorrhea
sneez
cough
sore
throat
serotypespecif
neutral
igm
igg
iga
antibodi
develop
infect
person
day
persist
year
protect
infect
partial
attribut
presenc
iga
antibodi
nasal
secret
recoveri
ill
depend
cellmedi
immun
hrvinduc
blastogenesi
natur
killer
cell
activ
mitogenstimul
cell
product
document
hrv
infect
hrv
induc
express
human
respiratori
epithelium
support
role
host
defens
hrv
infect
hrv
detect
respiratori
secret
isol
cultur
suscept
cell
line
hrv
shed
peak
around
hour
infect
declin
rapidli
may
remain
low
level
week
cultur
kept
roller
drum
examin
day
presenc
hrv
indic
typic
cpe
confirm
acid
sensit
isol
rapid
immunocytochem
method
avail
larg
number
serotyp
rtpcr
clinic
sampl
sensit
less
tediou
hrv
isol
recent
introduc
realtim
pcrbase
assay
sensit
convent
rtpcr
pcrbase
assay
use
studi
assess
impact
hrv
differ
set
homotyp
natur
hrv
antibodi
restrict
serolog
experiment
set
trial
antivir
agent
hrv
conduct
specif
treatment
suitabl
routin
use
yet
identifi
mainli
lack
potenc
untoward
side
effect
drug
deliveri
problem
ruprintrivir
select
inhibitor
hrv
proteas
potent
broadspectrum
antihrv
activ
vitro
doubleblind
placebocontrol
clinic
trial
intranas
ruprintrivir
experiment
hrv
infect
reduc
symptom
also
decreas
viral
titer
nasal
discharg
symptomat
relief
cold
symptom
obtain
broad
varieti
nonprescript
medic
system
sympathomimet
decongest
pseudoephedrin
may
reduc
nasal
obstruct
firstgener
antihistamin
may
reduc
sneez
rhinorrhea
nonsteroid
antiinflammatori
drug
naproxen
ibuprofen
may
reduc
headach
cough
system
symptom
larg
number
hrv
serotyp
minim
crossantigen
hamper
develop
hrv
vaccin
may
possibl
reduc
exposur
hrv
hand
wash
contact
cold
suffer
handl
object
may
contamin
respiratori
secret
studi
experiment
infect
volunt
show
applic
virucid
agent
salicyl
acid
pyroglutam
acid
hand
reduc
recoveri
rhinoviru
hand
skin
treat
person
compar
control
result
suggest
rhinoviru
transmiss
prevent
virucid
hand
treatment
shortterm
postexposur
prophylaxi
intranas
significantli
reduc
incid
hrv
cold
household
contact
index
case
howev
cost
difficulti
make
drug
avail
home
time
fashion
reduc
util
approach
extend
use
popul
especi
tropic
countri
ruprintrivir
also
evalu
prophylaxi
hrv
cold
start
hour
prior
inocul
human
volunt
approach
reduc
proport
subject
posit
viral
cultur
viral
titer
affect
frequenc
cold
respiratori
infect
caus
adenovirus
among
frequent
ill
virus
caus
particularli
children
age
year
adenovirus
frequent
isol
ari
studi
tropic
countri
south
cone
south
america
adenovirus
second
frequent
viru
recov
children
hospit
ari
adenovirus
nonenvelop
icosahedr
dna
virus
genu
mastadenoviru
famili
adenovirida
adenovirus
distinguish
antigen
groupspecif
f
typespecif
antigen
genom
subtyp
identifi
restrict
site
map
adenoviru
capsid
consist
three
morpholog
antigen
function
distinct
type
capsom
hexon
penton
base
fiber
project
penton
base
hexon
penton
base
contain
complementfix
groupspecif
antigen
common
human
adenovirus
wherea
fiber
primarili
neutral
hemagglutinationinhibit
typespecif
antigen
adenovirus
commonli
accompani
small
singlestrand
dna
parvovirus
known
adenoassoci
virus
seem
caus
specif
diseas
peopl
antibodi
least
one
four
serotyp
adenoassoci
viru
age
year
fiber
protein
bind
host
cell
protein
coxsacki
adenoviru
receptor
car
immunoglobulin
superfamili
serv
highaffin
receptor
adenovirus
class
major
histocompat
complex
mhc
also
may
serv
receptor
adenoviru
ligandreceptor
interact
facilit
interact
penton
base
cell
surfac
integrin
trigger
entri
endocytosi
doublestrand
linear
genom
dna
transport
nucleu
earli
late
set
viral
gene
transcrib
result
mrna
code
structur
nonstructur
protein
viru
assembl
take
place
nucleu
infecti
cycl
complet
releas
million
virion
upon
cell
lysi
adenovirus
replic
well
continu
cell
line
epitheli
origin
hela
adapt
grow
human
embryon
lung
fibroblast
stabl
wide
ph
rang
resist
isopropyl
alcohol
ether
chloroform
stabl
week
room
temperatur
year
approxim
colder
lyophil
inactiv
sodium
hypochlorit
temperatur
minut
respiratori
transmiss
adenovirus
occur
age
prime
import
epidem
among
militari
recruit
ocular
transmiss
associ
swim
pool
physician
offic
steril
hand
wash
inadequ
asymptomat
infect
prolong
carrier
state
common
lownumb
adenoviru
serotyp
frequent
age
year
account
case
uri
approxim
case
lri
children
adult
adenovirus
occur
sporad
caus
mostli
uri
infect
adenovirus
type
usual
epidem
attack
rate
per
week
newli
assembl
militari
recruit
whose
adenoviru
carriag
rate
may
high
group
adenovir
syndrom
vari
mild
cold
sever
lri
overal
attack
rate
may
reach
individu
need
hospit
temper
climat
adenovir
infect
frequent
late
winter
spring
earli
summer
wherea
northeast
brazil
seem
occur
yearround
salvador
also
northeast
brazil
adenovirus
detect
children
younger
age
year
ari
daycar
center
tropic
area
incid
adenoviru
infect
militari
recruit
lower
differ
serotyp
may
involv
pharyngoconjunctiv
fever
commonli
caus
adenovirus
type
may
epidem
endem
among
children
summer
temper
climat
inadequ
chlorin
filtrat
swim
pool
lake
associ
epidem
incub
period
adenoviru
infect
averag
day
adenoviru
respiratori
diseas
may
involv
part
respiratori
tract
nonepidem
infect
asymptomat
fact
adenovirus
discov
propens
latenc
adenoid
tissu
southeast
brazil
adenovirus
detect
equal
frequenc
wheez
young
children
asymptomat
control
adenovir
ill
consist
febril
cold
children
fever
may
high
longlast
pharyng
common
may
associ
fever
pharyng
exud
granular
appear
mucosa
anterior
cervic
adenopathi
similarli
streptococc
pharyng
adenovirus
recov
case
pharyng
small
children
pharyng
may
concurr
pharyngoconjunctiv
fever
syndrom
caus
adenoviru
type
character
conjunct
frequent
unilater
may
last
week
preauricular
adenopathi
cough
rhiniti
malais
fever
frequent
complic
adenovir
cold
acut
otiti
media
occur
case
adenoviru
lri
consist
mainli
bronchiti
pneumonia
may
make
childhood
lri
temper
area
adenovirus
may
caus
perman
lung
parenchym
damag
especi
concurr
measl
epidem
adenovir
infect
militari
recruit
spectrum
clinic
manifest
rang
cold
sever
pneumonia
typic
howev
manifest
fever
pharyng
symptom
cough
chest
pain
headach
malais
overwhelm
pneumon
may
part
dissemin
adenovir
infect
newborn
infant
patient
immunodefici
includ
acquir
immunodefici
syndrom
aid
howev
frequent
concomit
respiratori
pathogen
aid
patient
high
preval
asymptomat
adenoviru
infect
shed
doubt
causal
role
adenoviru
patient
adenovirus
also
import
caus
epidem
keratoconjunct
adenovir
ari
selflimit
uncommonli
associ
death
perman
sequela
adenovirus
alon
associ
pathogen
recov
fatal
case
lri
argentina
adenovir
respiratori
diseas
result
necrosi
cell
airway
epithelia
viremia
may
result
dissemin
infect
immunocompromis
person
bronchiol
interstiti
pneumon
mononuclear
cell
infiltr
part
inflammatori
process
lung
remain
unclear
certain
strain
virul
other
exampl
genom
variant
associ
major
fatal
lower
respiratori
diseas
south
america
addit
lytic
infect
adenovirus
may
becom
latent
epitheli
lymphoid
cell
probabl
import
maintain
viru
popul
possibl
role
latent
adenoviru
pathogenesi
chronic
airway
inflamm
suggest
protect
adenoviru
infect
diseas
mainli
due
typespecif
neutral
antibodi
reinfect
mostli
asymptomat
may
occur
longliv
tcell
immun
respons
develop
infect
immunocompet
person
respons
recoveri
also
involv
tissu
patholog
chang
adenovirus
detect
respiratori
ocular
ear
secret
clinic
correl
requir
asymptomat
viru
shed
common
isol
adenovirus
cell
cultur
identif
constitut
standard
diagnost
method
direct
detect
viral
antigen
viral
dna
pcr
clinic
sampl
attract
rapid
altern
rapid
antigen
detect
immunochromatographi
around
sensit
comparison
cell
cultur
easili
use
pointofcar
diagnosi
adenoviru
howev
convent
realtim
pcr
sensit
cell
cultur
posit
result
pcr
interpret
caution
given
propens
adenovirus
caus
latenc
adenovirus
caus
characterist
cpe
varieti
cell
line
human
origin
mainten
cultur
week
combin
blind
passag
ie
passag
cell
even
without
obviou
cpe
see
develop
passag
may
increas
adenoviru
recoveri
inocul
cell
centrifug
follow
immunostain
may
shorten
detect
time
sever
serolog
test
detect
antibodi
common
hexon
antigen
howev
clinic
util
restrict
present
routin
effect
antivir
treatment
adenoviru
infect
success
therapi
sever
adenovir
infect
immunocompromis
patient
iv
ribavirin
report
cidofovir
shown
efficaci
rabbit
ocular
model
adenovir
infect
iododeoxyuridin
adenin
arabinosid
unsuccess
treatment
adenovir
keratoconjunct
live
vaccin
consist
wildtyp
adenoviru
packag
entericco
capsul
induc
immun
ensur
enter
infect
without
infect
respiratori
tree
approach
use
success
vaccin
militari
recruit
adenovirus
type
proper
steril
hand
wash
chlorin
prevent
adenoviru
spread
via
tonomet
hand
swim
pool
coronavirus
envelop
virus
distinct
virion
morpholog
display
wide
space
long
petalshap
spike
surfac
confer
crownlik
appear
origin
name
corona
envelop
contain
long
helic
nucleocapsid
singl
positivestrand
rna
kb
size
largest
known
viral
rna
genom
recent
three
human
coronavirus
hcov
known
exist
cov
associ
sever
acut
respiratori
syndrom
sarscov
recent
two
group
netherland
almost
simultan
publish
studi
result
identif
two
new
strain
hcov
hcovnl
addit
pcr
primer
direct
conserv
replicas
sequenc
anim
cov
led
identif
yet
anoth
hcov
detect
children
new
connecticut
symptom
ari
agent
design
hcovnh
like
repres
speci
hcovnl
basi
antigen
genet
studi
known
human
coronavirus
distribut
three
four
coronaviru
group
far
identifi
nh
nl
belong
group
belong
group
ii
sarscov
known
constitu
group
iv
group
iii
contain
known
human
virus
consist
avian
infecti
bronchiti
viru
coronaviru
rna
synthesi
occur
cytoplasm
via
negativestrand
rna
intermedi
viral
rna
possess
cap
follow
leader
sequenc
untransl
region
anoth
termin
untransl
region
follow
poli
tail
genom
polycistron
synthesi
subgenom
negativesens
rna
done
discontinu
transcript
origin
nest
set
subgenom
mrna
share
leader
sequenc
overlap
end
envelop
contain
structur
protein
spike
membran
e
envelop
case
group
ii
coronavirus
ha
hemagglutinin
glycoprotein
contain
neutral
tcell
epitop
function
cell
receptor
ligand
therebi
determin
tissu
tropism
protein
embed
envelop
interact
n
nucleocapsid
protein
matur
addit
nucleocapsid
envelop
protein
replicas
present
cell
infect
coronavirus
new
virion
assembl
bud
intracellular
membran
releas
vesicl
secretori
pathway
consid
second
rhinovirus
agent
common
cold
caus
infect
variabl
frequenc
depend
mainli
detect
method
season
studi
mild
upper
respiratori
tract
infect
adult
attribut
document
caus
cold
temper
region
impact
caus
respiratori
infect
tropic
region
defin
human
coronavirus
first
isol
england
almost
year
ago
human
organ
cultur
tracheal
nasal
tissu
rel
field
studi
base
hcov
isol
cell
cultur
like
virus
fastidi
propag
respiratori
isol
obtain
far
antigen
similar
either
agent
structur
featur
member
famili
protein
bind
metalloproteas
human
aminopeptidas
n
cell
surfac
entri
independ
enzymat
activ
receptor
hemagglutinin
bind
sialic
acid
present
glycoprotein
cell
surfac
interact
facilit
infect
best
knowledg
specif
receptor
identifi
agent
hcov
found
throughout
world
consid
second
frequent
caus
common
cold
account
averag
rate
respiratori
ill
gener
popul
unit
state
howev
rate
may
quit
variabl
year
year
rang
year
peak
activ
hcov
infect
occur
mainli
winter
spring
month
summer
activ
also
document
autumn
peak
rhinoviru
activ
adult
cold
neg
rhinoviru
posit
hcov
rtpcr
charlottesvil
va
caus
welldocu
winter
outbreak
interv
temper
region
similarli
winter
outbreak
also
detect
europ
contrast
littl
known
preval
tropic
countri
brazil
activ
caus
respiratori
infect
nonhospit
children
first
document
serolog
earli
seroposit
rate
adult
complement
fixat
assay
usual
manifest
hcov
infect
typic
common
cold
incub
period
tend
day
longer
rhinoviru
cold
ill
durat
day
lowgrad
fever
may
occur
patient
addit
nasal
symptom
cough
sore
throat
occur
frequent
seriou
infect
lower
respiratori
tract
caus
hcov
also
document
either
sporad
infant
pneumonia
immunocompromis
patient
previous
healthi
marin
corp
recruit
pneumonia
addit
recogn
associ
influenzalik
ill
frail
elderli
patient
eight
nasopharyng
swab
older
patient
hospit
cardiopulmonari
ill
influenza
season
outbreak
rochest
ny
posit
hcov
five
respiratori
hcov
infect
associ
exacerb
asthma
chronic
bronchiti
recurr
wheez
children
hcov
detect
rtpcr
episod
asthma
children
year
old
england
brazil
hcov
detect
respiratori
sampl
children
younger
year
age
came
er
wheez
similarli
hrv
hcov
infect
frequent
recogn
associ
otiti
media
maxillari
sinus
children
adult
hcov
detect
rtpcr
middl
ear
effus
nasopharyng
aspir
children
acut
otiti
media
finland
nasal
swab
adult
acut
maxillari
sinus
conveni
small
anim
model
studi
pathogenesi
hcov
human
natur
experiment
infect
sourc
inform
obtain
vivo
hcov
transmit
respiratori
rout
experiment
infect
volunt
shed
viru
approxim
day
begin
hour
infect
approxim
time
onset
symptom
peak
symptom
occur
day
postinocul
known
infect
airway
epitheli
cell
apic
surfac
receptor
constitut
express
exit
product
infect
cell
rout
ultrastructur
studi
nasal
epithelium
volunt
experiment
infect
reveal
significantli
greater
epitheli
cell
damag
ciliari
loss
cytolysi
virusinocul
subject
shaminocul
one
day
postinfect
unit
state
seroposit
rise
first
year
life
around
adult
seroposit
symptomat
reinfect
possibl
despit
presenc
antibodi
suggest
rapidli
wane
immun
respons
circul
close
relat
antigen
differ
virus
sever
studi
indic
respiratori
hcov
abl
reach
central
nervou
system
recent
report
tempor
associ
hcovnh
infect
kawaski
diseas
await
confirm
laboratori
diagnosi
clinic
sampl
isol
tediou
two
best
character
strain
hcov
difficult
grow
routin
cell
cultur
sinc
primer
develop
rel
constant
part
genom
rtpcrbase
assay
recent
becom
best
altern
method
detect
recent
quantit
realtim
pcrbase
assay
hcov
develop
provid
faster
mean
detect
determin
viral
load
potenti
applic
clinic
studi
serolog
diagnosi
hcov
eia
sensit
specif
use
epidemiolog
survey
intranas
interferon
protect
experiment
infect
specif
antivir
therapi
avail
treatment
hcovinduc
cold
remain
larg
symptomat
vaccin
current
avail
hcov
hcov
fulfil
koch
postul
caus
agent
sar
share
structur
featur
genom
organ
famili
coronavirida
fig
prompt
recognit
peculiar
morpholog
coronaviru
electron
microscop
studi
vero
cell
inocul
oropharyng
materi
patient
initi
find
result
identif
sarscov
viral
genom
nucleotid
length
open
read
frame
code
put
protein
unknown
function
sarscov
phylogenet
differ
equidist
previous
known
coronavirus
isol
differ
origin
rel
homogen
genet
genom
analysi
reveal
sarscov
neither
hostrang
mutant
recombin
respiratori
tract
viral
infect
previous
known
coronavirus
rather
independ
emerg
viru
sarscov
seem
evolv
anim
sarslik
viru
acquir
greater
fit
human
cours
outbreak
probabl
appear
nucleotid
delet
open
read
frame
also
noteworthi
genet
signatur
present
genom
allow
differenti
isol
obtain
differ
cluster
replic
cycl
sarscov
thought
follow
main
step
coronavirus
sar
coronaviru
sarscov
probabl
emerg
around
novemb
provinc
guangdong
china
serolog
evid
infect
caus
viru
sera
healthi
human
sampl
prior
time
begin
outbreak
mani
affect
individu
guangdong
directli
indirectli
involv
game
trade
inde
palm
civet
raccoon
dog
wildgam
market
area
later
found
harbor
cov
homolog
sarscov
nucleotid
level
suggest
animaltohuman
interspeci
transmiss
involv
outbreak
provid
sourc
agent
later
adapt
effici
humantohuman
transmiss
interestingli
shortli
lift
wildlif
trade
ban
origin
impos
control
sar
outbreak
new
case
detect
guangdong
caus
virus
newli
introduc
anim
sinc
ban
reinstal
natur
acquir
human
case
sar
guangdong
remark
serum
sampl
adult
recruit
hong
kong
test
posit
sarscov
antibodi
suggest
small
proport
healthi
peopl
hong
kong
oppos
guangdong
china
expos
sarsrel
virus
least
year
outbreak
probabl
sarscov
precursor
previous
cross
speci
barrier
may
even
caus
subclin
human
infect
perhap
occasion
event
gener
strain
adapt
success
humantohuman
transmiss
sarscov
mainli
transmit
human
deposit
infect
droplet
aerosol
respiratori
epithelium
number
confirm
secondari
case
gener
one
index
case
sar
rel
low
rang
suggest
rel
ineffici
transmiss
addit
transmiss
infrequ
first
day
ill
partli
low
viral
load
respiratori
secret
phase
reason
complet
understood
sar
patient
identifi
superspread
disproportion
contribut
gener
high
number
secondari
case
excret
sarscov
sputa
stool
may
averag
day
respect
symptom
onset
excret
period
prolong
day
document
stool
prolong
shed
viru
fece
rais
possibl
oralfec
transmiss
fact
one
outbreak
sar
attribut
faulti
sewag
system
casefat
rate
estim
base
case
admit
hospit
around
patient
younger
age
older
age
year
howev
like
casefat
rate
base
infect
occur
commun
would
lower
transmiss
sarscov
among
healthcar
worker
patient
hospit
set
play
pivot
role
outbreak
propag
analysi
data
initi
outbreak
indic
close
contact
import
factor
lead
nosocomi
transmiss
agent
despit
lack
complet
studi
sensit
sarscov
differ
environment
condit
report
sarscov
persist
day
environment
surfac
day
diarrheal
stool
median
incub
period
sar
day
clinic
symptom
sign
sar
appear
day
exposur
system
symptom
fever
chill
myalgia
malais
usual
appear
first
respiratori
symptom
appear
day
later
repres
frequent
nonproduct
cough
dyspnea
chest
pain
headach
sore
throat
diarrhea
vomit
may
occur
chest
radiogram
frequent
reveal
infiltr
consist
viral
pneumon
consist
mostli
consolid
groundglass
opacif
comput
tomographi
ct
scan
patient
normal
equivoc
chest
radiogram
may
show
unilobar
multilobar
abnorm
fever
gener
subsid
hour
one
two
relaps
within
day
frequent
observ
lymphopenia
reduct
cell
slight
decreas
platelet
count
prolong
coagul
profil
elev
serum
enzym
lactic
dehydrogenas
ldh
creatinin
kinas
ck
creactiv
protein
crp
often
observ
around
one
third
patient
may
lymphocyt
count
cellsmm
higher
suscept
secondari
infect
wateri
diarrhea
averag
six
evacu
per
day
common
radiolog
worsen
pulmonari
lesion
seen
admiss
without
appear
new
lesion
frequent
observ
develop
diffus
groundglass
chang
frequent
herald
develop
acut
respiratori
distress
syndrom
ard
hypoxemia
note
approxim
half
patient
around
day
onset
symptom
high
proport
admit
intens
care
unit
icu
especi
older
male
requir
mechan
ventil
around
day
develop
spontan
pneumomediastinum
followup
uncommon
probabl
consequ
ruptur
peripher
lung
lesion
pleural
space
prognosi
relat
level
viral
replic
tissu
patient
high
viral
load
serum
nasopharyng
aspir
fece
well
viru
detect
multipl
site
tend
poor
clinic
outcom
addit
old
age
sever
underli
diseas
ck
crp
level
identifi
predictor
poor
outcom
ntermin
portion
spike
glycoprotein
need
viru
attach
viru
receptor
identifi
metallopeptidas
angiotensinconvert
enzym
homolog
unclear
whether
mechan
entri
conting
phdepend
endocytosi
inconsist
sarscov
tissu
distribut
suggest
may
receptor
coreceptor
molecul
may
need
cell
infect
sarscov
spike
protein
also
bind
dendrit
cellspecif
ctype
lectin
intercellular
adhes
molecul
nonintegrin
dcsign
result
dendrit
cell
infect
agent
allow
sarscov
transport
suscept
target
cell
elsewher
sarscov
detect
studi
use
differ
combin
immunohistochemistri
situ
hybrid
electron
microscopi
pneumocyt
apic
surfac
enterocyt
mark
inflammatori
infiltr
mucos
atrophi
observ
intestin
pathogenesi
sarscovrel
diarrhea
remain
larg
unknown
sarscov
viral
load
upper
airway
low
initi
day
peak
day
ill
quantit
rtpcr
sarscov
nasopharyng
aspir
patient
test
posit
admiss
reveal
viral
load
around
copiesml
day
clinic
onset
peak
copiesml
day
higher
viral
load
detect
lower
respiratori
tract
upper
airway
pulmonari
tissu
show
diffus
alveolar
damag
mix
infiltr
lung
edema
hyalin
membran
abund
macrophag
alveoli
interstitium
syncytia
format
besid
respiratori
secret
stool
sarscov
detect
urin
patient
titer
averag
copiesml
associ
abnorm
urinalysi
result
effect
sarscov
infect
immun
system
highlight
pronounc
tcell
lymphopenia
elev
sever
inflammatori
cytokin
chemokin
observ
sar
patient
like
involv
lung
monocyticmacrophag
infiltr
role
firmli
establish
sinc
viral
diseas
associ
elev
influenza
includ
promin
histolog
featur
addit
sinc
immunolog
marker
peripher
blood
may
reflect
happen
microenviron
lung
pathogen
import
find
clear
coinherit
hlab
higher
among
sar
patient
gener
popul
favor
role
genet
background
suscept
sarscov
pathogenesi
tcell
lymphopenia
remain
unknown
seroconvers
document
patient
around
day
rise
igg
titer
correl
decreas
viral
load
paradox
clinic
worsen
also
occur
phase
suggest
rather
uncheck
viral
replic
immunopatholog
factor
may
respons
lung
lesion
infect
experiment
anim
cynomolgu
macaqu
ferret
cat
golden
syrian
hamster
mice
african
green
monkey
induc
diseas
mimic
human
model
import
studi
pathogenesi
develop
vaccin
therapi
addit
develop
infecti
cdna
clone
sarscov
permit
revers
genet
experi
may
help
elucid
determin
viral
pathogenesi
low
viral
load
upper
respiratori
tract
first
day
ill
account
rel
poor
sensit
firstgener
rtpcr
diagnosi
period
sarscov
detect
rtpcr
nasopharyng
aspir
one
third
patient
present
two
third
day
rtpcr
may
posit
sarscov
stool
much
patient
day
urin
sampl
day
test
multipl
nasopharyng
serum
fecal
sampl
increas
sensit
diagnosi
rtpcr
overcom
low
sensit
convent
rtpcr
quantit
realtim
pcrbase
assay
sarscov
develop
improv
sensit
turnaround
time
allow
amplif
analysi
done
close
system
thu
reduc
crosscontamin
addit
capabl
assay
quantit
viral
load
contribut
understand
viral
pathogenesi
also
predict
outcom
sinc
high
viral
load
associ
poor
prognosi
abil
grow
sarscov
vero
cell
cultur
critic
identifi
agent
sarscov
recov
isol
respiratori
secret
fece
urin
first
week
ill
overal
sensit
rel
low
recoveri
like
success
respiratori
secret
stool
urin
recent
small
outbreak
sarscov
origin
laboratori
heighten
concern
laboratori
safeti
issu
regard
sar
specimen
guidelin
biosafeti
diagnosi
sar
updat
avail
web
site
recommend
propag
sarscov
cell
cultur
isol
prepar
viral
stock
cell
slide
perform
biosafeti
level
laboratori
wherea
handl
serum
blood
specimen
routin
test
serolog
perform
laboratori
nucleic
acid
extract
procedur
inocul
bacteri
mycolog
cultur
prepar
sampl
smear
done
laboratori
observ
work
practic
use
safeti
cabinet
seal
centrifug
protect
equip
bleach
spillag
decontamin
proper
wast
dispos
although
use
earli
diagnosi
seroconvers
determin
ifa
eia
remain
gold
standard
confirm
sar
diagnosi
igg
seroconvers
detect
patient
around
day
antibodi
crossreact
human
coronavirus
howev
rare
remain
possibl
therefor
confirm
posit
serolog
independ
neutral
assay
perform
avail
main
compon
treatment
sar
patient
support
therapi
chiefli
manag
hypoxemia
ard
outbreak
treatment
includ
broadspectrum
antivir
agent
ribavirin
immunosuppress
dose
corticosteroid
aim
reduc
immunopatholog
damag
lung
use
highdos
steroid
therapi
controversi
part
support
anecdot
evid
wherea
use
ribavirin
base
broad
antivir
spectrum
drug
howev
sarscov
modestli
suscept
ribavirin
vitro
therapeut
dose
difficult
achiev
clinic
sinc
becam
possibl
grow
sarscov
cultur
mani
potenti
antivir
compound
evalu
vitro
test
anim
model
even
fewer
clinic
test
interferon
leukocyt
hiv
proteas
inhibitor
consist
activ
vitro
may
consid
anim
test
clinic
trial
resolut
structur
sarscov
princip
proteas
prompt
studi
inhibitori
capac
known
antihiv
proteas
inhibitor
treatment
sar
one
openlabel
studi
combin
hiv
proteas
inhibitor
lopinavir
plu
pharmacokinet
booster
ritonavir
ribavirin
use
treat
sar
patient
outcom
compar
histor
control
treat
ribavirin
alon
day
onset
symptom
develop
ard
death
significantli
less
frequent
group
treat
combin
histor
control
addit
peak
viral
load
respiratori
sampl
stool
reduc
group
treat
combin
compar
control
howev
sinc
differ
outcom
predictor
sex
platelet
count
ldh
level
two
group
result
interpret
caution
preliminari
openlabel
studi
found
restrict
number
patient
treat
subcutan
interferon
associ
corticosteroid
show
reduc
oxygensatur
impair
faster
resolut
radiograph
chest
find
treat
corticosteroid
alon
convalesc
plasma
also
test
treatment
sar
patient
one
preliminari
uncontrol
studi
convalesc
plasma
may
reduc
frequenc
poor
outcom
given
day
ill
imposs
predict
whether
natur
reemerg
sarscov
would
like
caus
global
outbreak
nevertheless
vaccin
agent
would
relev
highrisk
individu
worker
laboratori
hospit
gameanim
farm
therefor
consider
effort
direct
develop
vaccin
shown
sarscov
spike
protein
produc
bacteria
express
chimer
parainfluenza
viru
well
spike
proteinencod
dna
induc
neutral
antibodi
protect
experiment
anim
challeng
live
viru
present
sarscov
vaccin
avail
human
use
therefor
absenc
persontoperson
transmiss
sarscov
worldwid
prevent
futur
outbreak
sar
requir
care
surveil
goal
maxim
earli
detect
new
case
sar
implement
control
measur
therebi
minim
social
disrupt
reach
goal
cdc
recommend
test
sarscov
patient
requir
hospit
radiograph
confirm
pneumonia
ard
without
identifi
etiolog
one
follow
risk
factor
day
onset
ill
travel
mainland
china
hong
kong
taiwan
close
contact
ill
person
histori
recent
travel
one
area
employ
occup
associ
risk
sarscov
exposur
eg
healthcar
worker
direct
patient
contact
worker
laboratori
contain
live
sarscov
belong
cluster
case
atyp
pneumonia
without
altern
diagnosi
updat
recommend
made
avail
cdc
web
site
http
wwwcdcgovncidodsar
time
overt
sar
activ
prevent
humantohuman
transmiss
pivot
curtail
outbreak
although
sar
infecti
rel
onset
termin
clinic
symptom
accur
determin
clear
shorten
time
onset
hospit
admiss
isol
reduc
risk
transmiss
thu
contribut
substanti
curtail
outbreak
identif
new
case
contact
trace
play
import
role
control
outbreak
regist
far
stringent
isol
procedur
must
adopt
confirm
suspect
case
requir
high
level
alert
among
healthcar
worker
earli
identif
sar
case
scenario
may
complic
situat
diseas
influenza
hantaviru
pulmonari
infect
may
occur
simultan
rate
transmiss
sarscov
among
healthcar
worker
vari
depend
stringenc
control
measur
adopt
presenc
socal
superspread
hospit
kind
activ
carri
personnel
especi
relat
proxim
index
case
assist
intub
suction
manipul
ventilatori
apparatus
seem
highrisk
activ
studi
conduct
differ
set
produc
conflict
result
one
studi
toronto
found
nurs
care
sar
patient
critic
care
unit
becam
infect
presenc
sever
wateri
diarrhea
may
add
challeng
infect
control
team
updat
set
recommend
healthcar
laboratori
personnel
avail
cdc
web
site
http
wwwcdcgovncidodsar
new
paramyxoviru
describ
netherland
associ
respiratori
ill
children
agent
first
detect
analysi
previous
unidentifi
viral
isol
induc
cytopath
effect
cell
cultur
isol
recov
period
respiratori
secret
children
ari
occur
winter
time
electron
microscopi
cell
cultur
isol
reveal
paramyxoviruslik
particl
rna
sequenc
reveal
genom
sequenc
organ
consist
paramyxoviru
subfamili
pneumovirina
close
relat
avian
pneumoviru
genu
metapneumoviru
rather
avian
viru
also
infect
human
agent
recogn
primarili
human
pathogen
thu
name
human
metapneumoviru
hmpv
hmpv
antibodi
detect
sera
collect
netherland
indic
agent
circul
least
decad
agent
hmpv
particl
envelop
pleomorph
spheric
filament
particl
mean
diamet
nm
complet
genom
sequenc
hmpv
avail
contrast
genom
organ
pneumovirus
metapneumovirus
differ
posit
gene
l
lack
gene
similar
hrsv
genet
antigen
studi
indic
hmpv
isol
cluster
two
main
serotyp
name
b
n
gene
sequenc
similar
nucleotid
level
subgroup
includ
two
genet
lineag
global
distribut
detail
studi
hmpv
replic
cycl
like
similar
human
paramyxovirus
hmpv
frequent
caus
communityacquir
ari
children
adult
contin
although
variabl
incid
differ
set
unit
state
hmpv
report
lower
respiratori
tract
ill
whose
etiolog
would
unidentifi
prior
develop
assay
detect
hmpv
canada
winter
season
hmpv
detect
patient
age
group
four
differ
provinc
similar
hrsv
hmpv
infect
frequent
colder
month
temper
region
differ
strain
subgroup
b
cocircul
year
howev
limit
knowledg
avail
hmpv
season
tropic
climat
peak
hmpv
activ
document
springsumm
hong
kong
south
africa
hmpv
detect
children
ari
admit
hospit
winter
season
hmpv
detect
alon
simultan
rsv
children
younger
year
age
admit
healthcar
facil
aracaju
northeast
brazil
month
april
may
interestingli
hmpv
detect
method
citi
follow
year
appar
variabl
hmpv
incid
year
year
also
observ
studi
conduct
argentina
itali
hmpv
frequenc
vari
three
consecut
annual
respiratori
viru
season
longterm
prospect
studi
need
establish
whether
season
pattern
hmpv
circul
tropic
region
world
clinic
hmpv
infect
resembl
close
caus
hrsv
rang
mild
upper
ari
sever
bronchiol
pneumonia
median
age
children
hospit
hmpv
infect
older
hrsv
hrsv
hospit
infant
young
children
may
requir
intens
care
mechan
ventil
dual
infect
hmpv
hrsv
appear
increas
likelihood
sever
ill
frequent
symptom
age
group
fever
dyspnea
cough
wheezingstridor
rhiniti
sore
throat
infect
children
one
studi
either
pneumonia
bronchiol
frequent
accompani
otiti
media
hmpv
may
caus
seriou
infect
patient
comorbid
immunosuppress
condit
well
young
elderli
one
studi
individu
older
lower
respiratori
infect
caus
hmpv
least
one
underli
chronic
debilit
condit
includ
lymphoma
leukemia
neurolog
cardiovascular
diseas
hmpv
infect
adult
may
present
influenzalik
ill
acut
bronchiti
common
cold
england
winter
hmpv
detect
rtpcr
associ
sampl
taken
patient
age
group
influenzalik
ill
neg
hrsv
influenza
virus
hmpv
increasingli
recogn
caus
acut
wheez
children
one
studi
conduct
finland
found
hmpv
wheez
children
present
significantli
higher
level
nasal
secret
compar
children
hrsvassoci
wheez
studi
conduct
brazil
found
children
hmpv
wheez
chest
indraw
previou
histori
asthma
frequent
associ
hmpv
hrsv
infect
hmpvinfect
patient
often
treat
bronchodil
corticosteroid
hrvsinfect
patient
littl
known
specif
mechan
pathogenesi
host
immun
respons
hmpv
infect
hmpv
pathogen
upper
lower
respiratori
tract
hmpv
replic
effici
respiratori
tract
monkey
viru
shed
peak
day
follow
infect
serolog
data
indic
hmpv
infect
young
individu
age
virtual
children
becom
seroposit
agent
reinfect
later
age
common
interestingli
coinfect
hmpv
report
correl
increas
sever
hrsv
infect
studi
conduct
unit
kingdom
found
coinfect
caus
tenfold
increas
rel
risk
admiss
icu
mechan
ventil
children
hrsv
bronchiol
similar
find
also
report
germani
hmpv
isol
cell
nasal
aspir
nasopharyng
swab
cytopath
effect
characterist
neg
hemadsorpt
test
develop
usual
late
inocul
day
sensit
rtpcr
assay
agent
develop
mani
differ
laboratori
rapidli
becom
standard
hmpv
diagnosi
realtim
pcr
assay
hmpv
show
sensit
convent
rtpcr
even
hybrid
use
increas
sensit
detect
amplicon
gener
convent
method
use
realtim
pcr
hmpv
detect
sampl
collect
patient
ari
australia
march
octob
neg
pathogen
support
measur
oxygen
therapi
bronchodil
corticosteroid
mechan
ventil
specif
antivir
treatment
agent
ribavirin
inhibitori
hmpv
vitro
although
hmpv
vaccin
avail
time
demonstr
hamster
ferret
african
green
monkey
suscept
infect
hmpv
hamster
vaccin
serotyp
